Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.52 |
| ▸ | MAOA | P21397 | 5/20 | 0.52 |
| ▸ | CALML3 | P27482 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6968254 | 1.00 | MAOB (0.52) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6972540 | 0.90 | F10 (0.44) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6970309 | 0.89 | MAOB (0.50) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6968449 | 0.89 | MAOB (0.50) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6972140 | 0.87 | MAOA (0.60) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6966689 | 0.85 | MAOB (0.49) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6961081 | 0.85 | MAOB (0.41) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL6964490 | 0.85 | MAOA (0.46) | MAOBMAOACALML3TP53GAA | |
| SCHEMBL27458038 | 0.85 | MAOA (0.46) | MAOBMAOACALML3TP53GAA | |
| SCHEMBL6964604 | 0.83 | MAOA (0.50) | MAOBMAOACALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181288-B1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | UPJOHN CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN | 2002-10-03 | — | — | US | disclosed |
| US-6387896-B1 | GRAMNEGATIVE, GRAMPOSITVE BACTERIA | PHARMACIA & UPJOHN CO. | 2002-05-14 | — | — | US | disclosed |
| EP-1181288-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000073301-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | OXA1L, MRPL21, RPS4Y1 | MAOB 1600/4885MAOA 1716/4885CALML3 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.